Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$16.07MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adrian H. Gottschalk
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Beta
- 2.86
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.45
Financials
Revenue
$16.07M+8878.8%Net Income
$-7.19MEBITDA
$-6.99MFree Cash Flow
$-18.95MEPS (diluted)
$-0.10Shares Outstanding (diluted)
70.63M+259.8%Operating Expenses
$24.88MCash & Debt
$167.58MReturn of Capital
$49.77MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $30.91M | $-74.28M | $-1.18 |
| 2024 | $22.60M | $-86.62M | $-1.58 |
| 2023 | $34.16M | $-98.43M | $-2.34 |
| 2022 | $19.23M | $-108.88M | $-2.62 |
| 2021 | $1.32M | $-101.32M | $-2.78 |
| 2020 | $430.0K | $-68.80M | $-1.90 |
| 2019 | $0.00 | $-51.13M | $-1.40 |
| 2018 | $0.00 | $-26.34M | $-1.34 |
Valuation
FHTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
123+76.19%Social Signal Score
Mentions (5)
- Newsbenzinga.com·4d ago·Negative
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data.
View source ↗ - Newsbarrons.com·5d ago·Negative
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
View source ↗ - Newsglobenewswire.com·5d ago·Negative
…o the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase.
View source ↗ - Newszacks.com·40d ago·Neutral
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·52d ago·Positive
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.23 per share
Typical surprise +9.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.10 vs $-0.24beat
- Thu, May 7$-0.29 vs $-0.28miss
- Wed, Mar 11$-0.34 vs $-0.28miss
- Wed, Nov 5$-0.25 vs $-0.31beat
- Tue, Aug 5$-0.28 vs $-0.31beat
- Wed, May 14$-0.30 vs $-0.30beat
Estimates and results for FHTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FHTX officers and directors.
- Bought
- $363
- Sold
- $3.4m
2 trades
8 trades
- Costa Carlossold
- Costa Carlossold
- Costa Carlossold
- Costa Carlossold
- Costa Carlossold
- Bellon Steven F.sold
- Flagship Pioneering Inc.bought
- Flagship Pioneering Inc.bought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FHTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.